Collaborative academic medical product development: An 8-year review of commercialization outcomes at the Institute of Translational Health Sciences

Abstract

IntroductionThe Institute of Translational Health Sciences (ITHS), a Clinical and Translational Science Award (CTSA)-funded program at the University of Washington (UW), established the Drug and Device Advisory Committee (DDAC) to provide product-specific scientific and regulatory mentoring to investigators seeking to translate their discoveries into medical products. An 8-year retrospective analysis was undertaken to evaluate the impact of the DDAC programs on commercialization metrics.MethodsTracked metrics included the number of teams who consulted with the DDAC, initiated a clinical trial, formed a startup, or were successful obtaining federal small business innovation awards or venture capital. The review includes historical comparisons of the startup rates for the UW School of Medicine and the Fred Hutchinson Cancer Research Center, two ITHS-affiliated institutions that have had different DDAC utilization rates.ResultsBetween 2008 and 2016, the DDAC supported 161 unique project teams, 28% of which went on to form a startup. The commercialization rates for the UW School of Medicine increased significantly following integration of the DDAC into the commercialization programs offered by the UW technology transfer office.ConclusionsA formalized partnership between preclinical consulting and the technology transfer programs provides an efficient use of limited development funds and a more in-depth vetting of the business opportunity and regulatory path to development.

A reconsideration of university gap funds for promoting biomedical entrepreneurship

“…LEAP's support of university commercialization through funding and expert guidance aligns with other gap funds and proof of concept programs described in the literature [8,9,[14][15][16]. Consistent with our results, previous studies have also noted an increase in start-up formation after the introduction of these programs [9,17].…”

Areas of strength and opportunities for growth in translational science education and training: Results of a scoping review from the NCATS Education Branch

“…Another article, by Rios et al, 63 focused on describing the evaluation of an E&T opportunity described in a separate article 41 . Of these 15 articles, two‐thirds ( n = 10; 67%) used a post‐experience data collection approach, involving a survey, discussion group, or interviews with participants 35,36,45,46,50,56,58,60,61,63 . Another third ( n = 5; 33%) used both pre‐ and post‐experience data collection, including participant surveys and knowledge tests 39,43,48,53,57 .…”

Software to manage regulatory workflows for medical device development at academic medical centers: A critical gap

“…A common feature of these programs is individualized support from advisory committees on medical, engineering, regulatory, and marketing processes. These committees comprise individuals with extensive experience in the MedTech industry and provide valuable feedback based on investigator progress reports [9,10]. However, these programs are difficult to scale due to their reliance on limited numbers of experts.…”